GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Karyopharm Therapeutics
Karyopharm is a biopharmaceutical company specializing in cancer treatment. Its stock price is driven by sales of its flagship drug, Xpovio, and success in expanding its use to new types of cancer.
Share prices of companies in the market segment - Oncology targeted therapy
Karyopharm Therapeutics is an oncology company developing and commercializing targeted drugs that interfere with the nuclear protein export mechanism. We've categorized it as a "Targeted Oncology" company. The chart below shows how the market is evaluating new approaches to cancer treatment.
Broad Market Index - GURU.Markets
Karyopharm Therapeutics is an oncology company developing and commercializing targeted therapies that interfere with the nuclear protein export pathway. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
KPTI - Daily change in the company's share price Karyopharm Therapeutics
For Karyopharm Therapeutics, an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to sales data for its drugs and the results of new clinical trials.
Daily change in the price of a set of shares in a market segment - Oncology targeted therapy
Karyopharm Therapeutics Inc. is an oncology company. This chart illustrates the extreme volatility of the biotech sector. Comparing it to KPTI, whose success depends on sales of its drugs, helps assess its risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Karyopharm Therapeutics is a biotech company focused on developing targeted therapies for cancer treatment. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Karyopharm Therapeutics
Karyopharm Therapeutics' year-over-year performance is a story about the commercialization of its targeted drug Xpovio. Its market capitalization growth over the past 12 months reflects sales of this drug for the treatment of multiple myeloma, as well as the results of studies on its use in other cancer types, which is key to its market expansion.
Annual dynamics of market capitalization of the market segment - Oncology targeted therapy
Karyopharm Therapeutics Inc. is a commercial biopharmaceutical company focused on developing and commercializing innovative cancer treatments. This chart shows how its commercialization success, clinical trial results, and competitive environment impact its performance in the oncology sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Karyopharm, as an oncology company, operates in the world of science, not economics. Its stock price is determined by the sales success of its drugs and progress in clinical trials. The company's chart tells the story of a biotech company fighting for market share in a market where one successful drug can change everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage oncology company. Its monthly performance reflects both sales growth of its approved drug, Xpovio, and progress in clinical trials to expand its use. Quarterly revenue reports are the primary indicator of its health.
Monthly dynamics of market capitalization of the market segment - Oncology targeted therapy
Targeted therapy in oncology is a segment where commercial success depends on sales of approved drugs and pipeline development. The dynamics of this sector, shown in the chart, reflect investors' assessment of these factors. Karyopharm Therapeutics operates in this environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Karyopharm, a biopharmaceutical company focused on oncology, moves to the rhythm of news about its drug sales and new research results. Its shares are volatile and uncorrelated with the broader market, which is typical for biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Karyopharm Therapeutics
For Karyopharm, an oncology company with an already approved drug, weekly performance depends on sales data and clinical trial news. Results from trials for new indications for its drug can cause sharp and significant fluctuations.
Weekly dynamics of market capitalization of the market segment - Oncology targeted therapy
Karyopharm and the entire oncology biotech sector are riding the same news and sentiment. Breakthroughs in targeted therapies or changes in FDA policy could boost the entire industry. The chart shows how a company with an already approved product fares in this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Karyopharm and the entire oncology biotech sector are riding the same news and sentiment. Breakthroughs in targeted therapies or changes in FDA policy could boost the entire industry. The chart shows how a company with an already approved product fares in this high-risk segment.
Market capitalization of the company, segment and market as a whole
KPTI - Market capitalization of the company Karyopharm Therapeutics
The Karyopharm market capitalization chart is the financial valuation of the biopharmaceutical company whose drug Xpovio is approved for the treatment of blood cancer. It reflects both the drug's commercial potential and its potential for use in other diseases. Its dynamics reflect the balance between current sales and the results of new clinical trials.
KPTI - Share of the company's market capitalization Karyopharm Therapeutics within the market segment - Oncology targeted therapy
Karyopharm Therapeutics is a commercial biopharmaceutical company focused on developing and commercializing novel nuclear-targeted cancer therapies. Its sector share reflects the success of its approved drug, XPOVIO. The chart below shows this innovator's position in the oncology field.
Market capitalization of the market segment - Oncology targeted therapy
Karyopharm Therapeutics is developing a new class of cancer drugs aimed at nuclear export. The chart below shows the total market capitalization of the entire oncology sector. Its dynamics reflect the search for new mechanisms to combat tumors. Karyopharm is a pioneer in its unique approach.
Market capitalization of all companies included in a broad market index - GURU.Markets
Targeted cancer therapy, as seen in the graph, is exploring new mechanisms. Karyopharm Therapeutics is developing drugs that block the XPO1 protein, preventing tumor suppressor proteins from exiting the cell nucleus. Its capitalization is a risky bet on this unique mechanism of action.
Book value capitalization of the company, segment and market as a whole
KPTI - Book value capitalization of the company Karyopharm Therapeutics
Karyopharm's book value is capital invested in fighting cancer through nuclear transport. Currently in the R&D and commercialization phases, the company uses its assets to develop and commercialize drugs that block the release of tumor suppressor proteins from the cell nucleus.
KPTI - Share of the company's book capitalization Karyopharm Therapeutics within the market segment - Oncology targeted therapy
Karyopharm Therapeutics, a biopharmaceutical company that commercialized its first drug, has R&D and operational infrastructure. Its stake in the sector's assets reflects its ownership of laboratories and offices to support the research and global sales of its oncology drug.
Market segment balance sheet capitalization - Oncology targeted therapy
Karyopharm Therapeutics is a commercial oncology company. Its model is moderately capital-intensive. In addition to R&D, it has a commercial infrastructure for its drug, XPOVIO. Compared to the biotech sector, it is heavier than R&D-heavy companies, but lighter than giants with their own manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
Karyopharm's assets aren't based on an extensive catalog, but rather on deep expertise in nuclear export inhibitors—a new class of cancer drugs. The company's balance sheet reflects the value of its approved drug and its research and development. The chart shows the capital behind this pioneer in targeted therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Karyopharm Therapeutics
Karyopharm Therapeutics is an oncology company with an approved drug. Its market capitalization reflects the current sales of this drug and its potential for use in treating other cancers, as well as the value of its pipeline.
Market to book capitalization ratio in a market segment - Oncology targeted therapy
Karyopharm Therapeutics is an oncology company with an approved drug on the market. Its valuation is a balance between current sales and the potential for new research. This chart shows how the market views its commercial success and research pipeline.
Market to book capitalization ratio for the market as a whole
Karyopharm Therapeutics is an oncology company developing targeted therapies. Its value is determined almost entirely by the potential of its scientific developments and the success of clinical trials. This chart demonstrates how biotech market valuations are based on future scientific breakthroughs rather than current tangible assets.
Debts of the company, segment and market as a whole
KPTI - Company debts Karyopharm Therapeutics
Karyopharm Therapeutics is an oncology company with drugs already on the market. The company is now focusing on expanding commercial reach and conducting research into new indications. Debt financing could be used to fund these costly clinical trials and marketing efforts.
Market segment debts - Oncology targeted therapy
Karyopharm Therapeutics is an oncology company with an approved drug on the market. Following commercialization, its financial strategy changes. This chart shows how the company uses sales revenue and its balance sheet to fund further research, expand the indications for its drug, and launch new candidates.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Karyopharm Therapeutics
Karyopharm Therapeutics, an oncology company with approved drugs already on the market, still incurs significant expenses on their promotion and further research. This chart shows its debt load. Even for a company with sales, high debt can be a risk if competition intensifies or sales fail to meet expectations.
Market segment debt to market segment book capitalization - Oncology targeted therapy
Karyopharm Therapeutics develops and markets drugs based on a novel mechanism of action—nuclear export inhibition—for the treatment of oncology. This chart compares the company's debt, used for commercialization and further research, to the total market capitalization of the entire targeted therapy sector.
Debt to book value of all companies in the market
Karyopharm Therapeutics is an oncology company developing and commercializing innovative drugs. Bringing a drug to market requires significant marketing and manufacturing costs. The chart shows how the company uses debt to finance its growth after approvals, which compares favorably with other commercial biopharmaceutical companies.
P/E of the company, segment and market as a whole
P/E - Karyopharm Therapeutics
For Karyopharm Therapeutics, an oncology company with an already approved drug, this chart is an assessment of its commercial success. The price-to-earnings ratio shows how investors view current and future sales. The price-to-earnings ratio reflects investors' reaction to revenue reports and news about the drug's expanded use.
P/E of the market segment - Oncology targeted therapy
This chart reflects the average valuation for the biopharmaceutical sector—the benchmark for Karyopharm. Comparing this company's valuation for an already approved drug with the industry average helps us understand how optimistic the market is about its commercial potential and future development pipeline.
P/E of the market as a whole
Karyopharm Therapeutics develops and markets drugs based on a novel mechanism of action—nuclear export inhibition—for the treatment of cancer. This chart shows sentiment in the biotech sector. It helps understand how the market views the commercial success of the company's already approved drug and the potential for its development to expand into new oncology indications.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Karyopharm Therapeutics
Karyopharm Therapeutics develops and markets drugs based on a novel mechanism of action—nuclear export inhibition—for the treatment of oncology. This chart reflects analyst expectations for sales growth of its already approved drug and success in clinical trials for new indications.
%20P%2FE%20Karyopharm%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Karyopharm-Therapeutics&v=1772642725715 "Chart of the company's future (projected) P/E Karyopharm Therapeutics")
Future (projected) P/E of the market segment - Oncology targeted therapy
Karyopharm Therapeutics is a pharmaceutical company focused on developing new drugs for the treatment of cancer and other diseases based on the inhibition of nuclear export. This chart compares its future revenue expectations with the oncology sector. It demonstrates how the market views its approved drug XPOVIO and the potential of its scientific platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-targeted-therapy&v=1772642725773 "Future (projected) P/E graph of the market segment - Oncology targeted therapy")
Future (projected) P/E of the market as a whole
Karyopharm Therapeutics is a biopharmaceutical company developing new drugs for the treatment of cancer. This chart shows the company's overall risk appetite. KPTI's success depends on the commercial success of its already approved drugs and the clinical trial results of its new ones. This is a story driven by science and sales, not general sentiment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772642725795 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Karyopharm Therapeutics
Karyopharm Therapeutics is a pharmaceutical company focused on developing and commercializing new drugs for the treatment of cancer and other diseases. Its drugs work through a novel mechanism, inhibiting nuclear export. This graph shows financial results, which are dependent on the success of its approved drugs and progress in clinical trials.
Profit of companies in the market segment - Oncology targeted therapy
Karyopharm Therapeutics is a biopharmaceutical company developing new cancer treatments that work through a novel mechanism by blocking the nuclear export of proteins. This chart illustrates the financial climate in the oncology sector, which is constantly seeking and funding innovative approaches to combat difficult-to-treat cancers.
Overall market profit
Karyopharm Therapeutics is a biopharmaceutical company specializing in cancer treatment. Demand for its drugs is driven by medical needs and is independent of economic conditions. This makes the company's business non-cyclical. However, a favorable investment climate, linked to overall market conditions, is essential for funding new research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Karyopharm Therapeutics
Karyopharm Therapeutics is a biopharmaceutical company whose lead drug is a first-in-class exportin 1 (XPO1) inhibitor for the treatment of cancer. This chart reflects analyst expectations for the expanded use of this unique drug across various cancer types.
%20profit%20of%20the%20company%20Karyopharm%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Karyopharm-Therapeutics&v=1772642725837 "Graph of future (projected) profit of the company Karyopharm Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology targeted therapy
Karyopharm Therapeutics is developing and commercializing a new class of drugs targeting the nuclear export mechanism for the treatment of oncology. This chart shows forecasts for the biotech sector. Karyopharm's profitability depends on the expansion of its currently approved drug and the success of other candidates in its pipeline in clinical trials.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-targeted-therapy&v=1772642725845 "Graph of future (predicted) profits of companies in a market segment - Oncology targeted therapy")
Future (predicted) profit of the market as a whole
Karyopharm Therapeutics develops innovative drugs for cancer treatment. Like many biotech companies, it relies on successful clinical trials and the ability to raise capital. This graph, which reflects earnings expectations, is an indicator of the overall investment climate and the market's willingness to fund long-term, risky research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772642725851 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Karyopharm Therapeutics
Karyopharm Therapeutics is a biopharmaceutical company developing and commercializing drugs to treat oncology. This chart shows how the market values the revenue from its approved drugs. It reflects both current sales and expectations for expanded use of its drugs.
P/S market segment - Oncology targeted therapy
Karyopharm Therapeutics is a biopharmaceutical company focused on developing new treatments for cancer and other diseases based on nuclear export inhibitors. This is a new class of drugs. This chart reflects the average biotech valuation, helping to understand how highly the market values this innovative scientific platform and its commercial products.
P/S of the market as a whole
Karyopharm Therapeutics is a biopharmaceutical company developing and commercializing drugs based on novel mechanisms of action for the treatment of cancer. Its revenue is generated by sales of its already approved drug. This chart helps assess the market perception of the company's current revenue and its potential to expand the use of its drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Karyopharm Therapeutics
Karyopharm Therapeutics develops and commercializes drugs based on a novel mechanism of action—nuclear export inhibition—for the treatment of cancer. This chart shows how investors estimate future revenue from sales of its currently approved drug and the potential of other candidates in the portfolio.
%20P%2FS%20Karyopharm%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Karyopharm-Therapeutics&v=1772642725863 "The graph of the company's future (projected) P/S Karyopharm Therapeutics")
Future (projected) P/S of the market segment - Oncology targeted therapy
Karyopharm Therapeutics develops and markets drugs based on a novel mechanism of action—nuclear export inhibition—for the treatment of cancer. This chart compares the company's estimated future sales with its industry. It reflects the market's assessment of the commercial success of its current drug and the potential of its other developments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-targeted-therapy&v=1772642725864 "Future (projected) P/S market segment graph - Oncology targeted therapy")
Future (projected) P/S of the market as a whole
Karyopharm Therapeutics is a commercial pharmaceutical company focused on developing new cancer treatments based on nuclear export inhibition. The optimism expressed by this indicator is often fueled by scientific breakthroughs. The success of Karyopharm's drugs in the treatment of blood cancers exemplifies how innovation creates new standards of therapy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772642725865 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage oncology company. Its revenue, shown in this chart, is generated from sales of its flagship drug, XPOVIO, which is approved for the treatment of multiple myeloma. The growth in this figure reflects increased prescriptions and expanded use of the drug.
Sales of companies in the market segment - Oncology targeted therapy
Karyopharm Therapeutics is a biopharmaceutical company that has developed and commercialized an innovative drug for the treatment of multiple myeloma. Their approach targets a new mechanism of action within cancer cells. This graph illustrates the dynamics of the oncology segment, where the commercial success of a single drug can radically transform a company.
Overall market sales
Karyopharm Therapeutics is a pharmaceutical company focused on developing new cancer treatments. Its operations require significant investment. The growth in total revenue, reflected in this chart, creates a favorable investment climate, facilitating the raising of capital needed to conduct costly clinical trials and bring products to market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Karyopharm Therapeutics
Karyopharm Therapeutics develops and markets innovative drugs based on a novel mechanism of action—nuclear export inhibition—for the treatment of cancer, particularly multiple myeloma. This chart reflects analysts' expectations for sales growth and expanded use of its already approved drug.
%20sales%20of%20the%20company%20Karyopharm%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Karyopharm-Therapeutics&v=1772642725889 "Schedule of future (projected) sales of the company Karyopharm Therapeutics")
Future (projected) sales of companies in the market segment - Oncology targeted therapy
Karyopharm Therapeutics develops and commercializes drugs based on a novel mechanism of action—nuclear export inhibition—for the treatment of cancer. This chart shows forecasts for the targeted oncology sector. It illustrates how new approaches to treating cancer at the cellular level are expanding doctors' arsenal.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-targeted-therapy&v=1772642725895 "Schedule of future (projected) sales of companies in the market segment - Oncology targeted therapy")
Future (projected) sales of the market as a whole
Karyopharm Therapeutics, an oncology company, sees this chart as an indicator of the overall health of the biotech sector. The positive economic outlook reflected here is fueling increased venture capital funding and M&A activity, creating a favorable environment for the development and commercialization of their targeted therapies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772642725903 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial pharmaceutical company with approved and marketed cancer treatments. This chart shows how well revenue from sales of its flagship drug, XPOVIO, covers all company expenses—from manufacturing to marketing and ongoing research—and translates into net profit.
Market segment marginality - Oncology targeted therapy
Karyopharm Therapeutics develops and commercializes cancer treatments based on a novel mechanism of action—nuclear export inhibition. Profitability for such a company depends on the successful sales of its approved drug and the effectiveness of its R&D. The chart shows how their scientific approach translates into financial performance.
Market marginality as a whole
Karyopharm Therapeutics develops and markets innovative cancer treatments based on novel mechanisms of action. Based on its overall profitability, Karyopharm is a commercial-to-market oncology company. Its profitability depends on sales of its approved drug and the success of its clinical development.
Employees in the company, segment and market as a whole
Number of employees in the company Karyopharm Therapeutics
Karyopharm Therapeutics is an oncology company that has developed and commercialized innovative drugs. This graph shows its team, including both researchers and a large commercial team. The size of its staff reflects its status as a full-service company, from lab to patient.
Share of the company's employees Karyopharm Therapeutics within the market segment - Oncology targeted therapy
Karyopharm Therapeutics has developed and commercialized innovative cancer treatments based on nuclear export inhibition. This chart shows the percentage of leading scientists and clinicians in this unique field of oncology that Karyopharm attracts. This reflects its scientific leadership and commercial success.
Number of employees in the market segment - Oncology targeted therapy
Karyopharm Therapeutics is a commercial biopharmaceutical company developing and marketing drugs for the treatment of oncology. Its staff includes both scientists and a large commercial team. This chart shows how the company is growing sales. Sales growth is an indicator of market expansion for its core product.
Number of employees in the market as a whole
Karyopharm Therapeutics develops innovative cancer treatments. In the oncology field, demand for new, more effective treatments is enormous and is not affected by economic cycles. This chart shows overall occupancy, but for Karyopharm, the growth driver is regulatory approvals of its drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics is a commercial-stage oncology company. This metric reflects both the value of its approved drugs (intellectual property) and the availability of a sales and marketing team. The graph shows the balance between R&D and commercial efficiency.
%20of%20the%20company%20Karyopharm%20Therapeutics%20(KPTI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Karyopharm-Therapeutics-KPTI&v=1772642726107 "Chart of market capitalization per employee (in thousands of dollars) of the company Karyopharm Therapeutics (KPTI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Karyopharm Therapeutics is a biopharmaceutical company focused on developing new cancer treatments. Its market valuation is based on the success and potential of its drugs. This metric reflects the value the market places on each employee who contributes to the development and commercialization of these life-saving drugs.
%20by%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-targeted-therapy&v=1772642726138 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology targeted therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Karyopharm Therapeutics is a biopharmaceutical company developing and marketing innovative cancer treatments. The company already has an approved product on the market. This chart shows how the market values a commercially successful biotech company, where revenue from sales of a single drug can support high earnings per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772642726180 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics is a biopharmaceutical company that already has an approved drug (Xpovio) for the treatment of cancer (multiple myeloma). This chart shows commercialization efficiency. It reflects how successfully their sales and marketing team promotes the drug, generating revenue per employee.
%20Chart%20Karyopharm%20Therapeutics%20(KPTI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Karyopharm-Therapeutics-KPTI&v=1772642726205 "Company Profit Per Employee (in thousands of dollars) Chart Karyopharm Therapeutics (KPTI)")
Profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy
Karyopharm Therapeutics (KPTI) is a biopharmaceutical company focused on targeted oncology. They already have an approved drug (Xpovio). This chart shows commercial performance. It reflects how successfully the sales and marketing department promotes the drug, and how the R&D team expands its use, generating revenue per employee.
%20in%20the%20market%20segment%20-%20Oncology%20targeted%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-targeted-therapy&v=1772642726221 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology targeted therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Karyopharm Therapeutics is a biopharmaceutical company with an approved oncology drug (Xpovio) already on the market. This graph shows the transition from R&D to the commercial stage. Now, profit per employee depends not only on the cost of scientists but also on the effectiveness of the sales team, which must recoup all previous development investments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772642726237 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics is a biopharmaceutical company developing innovative cancer treatments. This chart shows the commercial success of their approved drugs. Their high revenue per employee demonstrates that their drugs are in demand among oncologists, and their team is working effectively on their production and marketing.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Karyopharm-Therapeutics-KPTI&v=1772642726256 "Sales chart per company employee Karyopharm Therapeutics (KPTI)")
Sales per employee in the market segment - Oncology targeted therapy
Karyopharm Therapeutics is a biopharmaceutical company specializing in novel targeted cancer therapies (XPO1 inhibitors). This chart shows the average revenue per employee in the sector. For a company at the commercialization stage, this is an important indicator of how productive their commercial team is in advancing their unique drug in the oncology market.
Sales per employee for the market as a whole
Karyopharm Therapeutics (KPTI) is a biopharmaceutical company that already has an approved drug (Xpovio) for the treatment of cancer (multiple myeloma). This chart shows how successfully their commercial team is selling this drug to oncologists, generating revenue per employee, from R&D to sales.
Short shares by company, segment and market as a whole
Shares shorted by company Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics is an oncology company whose approved drug Xpovio is used to treat myeloma. However, the drug has serious side effects. The chart shows the number of investors betting that Xpovio will fail to expand its use and that its sales will be limited due to toxicity and competition from new treatments.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Karyopharm-Therapeutics-KPTI&v=1772642726294 "Short Shares Chart for the Company Karyopharm Therapeutics (KPTI)")
Shares shorted by market segment - Oncology targeted therapy
Karyopharm Therapeutics fights cancer with XPO1 inhibitors, a new class of drugs. This indicator measures overall skepticism in the pharmaceutical industry. When it's high, it indicates that investors generally don't believe clinical trials will be successful or anticipate funding challenges across the industry in the early stages.
Shares shorted by the overall market
Karyopharm Therapeutics develops and already markets innovative cancer drugs. Despite generating revenue, the company still invests in expensive R&D. This chart shows the overall level of fear. When investors are afraid, they look at profitability. KPTI, balancing between growth and losses, becomes vulnerable as the market doubts its ability to fund research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics focuses on a new targeted cancer therapy (XPO1 inhibitors). The company's shares react sharply to clinical trial data and FDA decisions. This oscillator measures the strength of these reactions, showing when the stock enters "overbought" territory (above 70) on good news or "oversold" territory (below 30) on a backdrop of disappointing news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Karyopharm-Therapeutics-KPTI&v=1772642726312 "RSI 14 indicator chart for the company's stock Karyopharm Therapeutics (KPTI)")
RSI 14 Market Segment - Oncology targeted therapy
Karyopharm (KPTI) is a "biotech" company, a cancer "blocker." Their specialty is XPO1 inhibitors (SINEs), which lock cancer-defending proteins inside the cell nucleus (for the treatment of myeloma). The "Oncology targeted therapy" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of this entire segment. It helps us understand: is KPTI's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Karyopharm Therapeutics (KPTI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KPTI (Karyopharm Therapeutics)
Karyopharm (KPTI) is an oncology company whose flagship drug (XPOVIO) uses an innovative mechanism of nuclear export inhibition to treat blood cancers. This chart shows the average 12-month forecast. It reflects analyst expectations for XPOVIO sales growth and success in its development for other tumors.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KPTI-Karyopharm-Therapeutics&v=1772642726338 "A chart showing analyst consensus forecasts for the expected stock price. KPTI (Karyopharm Therapeutics)")
The difference between the consensus estimate and the actual stock price KPTI (Karyopharm Therapeutics)
Karyopharm (KPTI) is an oncology company whose lead drug (Xpovio) is approved for myeloma but is struggling for market share. This chart is a barometer of their commercialization. It measures the gap between the price and the consensus target, reflecting whether analysts believe their drug can expand its reach and become a blockbuster.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KPTI-Karyopharm-Therapeutics&v=1772642726340 "A chart showing the difference between the consensus forecast and the actual stock price. KPTI (Karyopharm Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology targeted therapy
Karyopharm Therapeutics is an oncology company whose lead drug, Xpovio, is approved for the treatment of myeloma. It works through a novel mechanism, blocking the "export" of proteins from the cell nucleus. This chart shows general expectations for the targeted oncology sector, reflecting whether experts believe Xpovio will be commercially successful.
Analysts' consensus forecast for the overall market share price
Karyopharm is a commercial-stage biotech focused on oncology. This chart, which reflects the overall market appetite for risk, is vitally important. While cancer drugs are secure, biotech valuations are not. Optimism = investors are paying for growth. Pessimism = investors are fleeing high-risk sectors.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Karyopharm Therapeutics
Karyopharm Therapeutics is a biotech company whose fate is tied to their drug Xpovio. It's a first-in-class XPO1 inhibitor used to treat blood cancer (multiple myeloma). This chart is a summary indicator of their commercialization. It reflects their ability to grow Xpovio sales and their R&D efforts to expand its use to other cancer types.
AKIMA Market Segment Index - Oncology targeted therapy
Karyopharm Therapeutics (KPTI) is an oncology company that developed and commercialized the XPO1 inhibitor Selinexor (XPOVIO) for the treatment of multiple myeloma and other cancers. The chart shows the segment average. It helps investors assess how Karyopharm's market performance and risks compare to the average in the targeted therapy sector.
The AKIM Index for the overall market
Karyopharm Therapeutics is a commercial pharmaceutical company specializing in nuclear transport. It markets Xpovio for the treatment of multiple myeloma. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, struggling to grow sales and refinance, compares to overall trends.
